Silence Therapeutics Reports Results From Ongoing SANRECO Phase 1 Repeat Dose Study Of Divesiran; Says Data Support Advancing Divesiran Into Phase 2
Of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline.
To date, divesiran has been observed to be well tolerated with no major safety issues.